TransCode and BRAIN to Co-develop CRISPR-derived Technology Platform for Oncology
TransCode Therapeutics and BRAIN Biotech have entered a joint research and development agreement (JDA) with the objective to co-develop a
Read moreTransCode Therapeutics and BRAIN Biotech have entered a joint research and development agreement (JDA) with the objective to co-develop a
Read moreLonza and Context Therapeutics, a US-based clinical-stage biopharmaceutical company advancing therapeutics for solid tumors, announced that they have reached a
Read moreFrench clinical-stage biotech company Sensorion, which focuses on the creation of cutting-edge treatments to manage, prevent, and reverse hearing loss
Read moreEctica Technologies is delighted to sponsor the 5th Annual Oncology Strategy Meeting organized by Proventa International taking place on May
Read moreTremelimumab, in conjunction with Imfinzi, has been accepted under priority review for patients with unresectable liver cancer in the United
Read moreAmerican multinational pharmaceutical company Bristol Myers Squibb has announced that OpdualagTM , a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as one intravenous infusion,
Read moreBased on data obtained from Phase II and the Phase I studies, Abecma has received approval in Japan for the
Read moreThe novel 3DProSeed ® StromaLine ® developed by Ectica is an advantageous collection of pre-developed and well characterized stromal models
Read moreFrench pharma giant Sanofi and British pharmatech business Exscientia revealed a ground-breaking research cooperation and licensing agreement to develop up
Read moreRhizen Pharmaceuticals has started dosing in a phase I/Ib trial to assess the efficiency of PARP inhibitor (RP12146) in advanced
Read more